Navigation Links
CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
Date:11/9/2008

l impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir.

Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume substantial quantities of alcohol.

CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose.

In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%).

Please see accompanying full Prescribing Information. If you have any questions concerning CRESTOR, please contact AstraZeneca at 1-800-237-8898. CRESTOR is a registered trademark of the AstraZeneca group of companies.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
4. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
5. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
6. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
11. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Sept. 3, 2015  Ascendis Pharma A/S ... biotechnology company that applies its innovative TransCon ... today announced plans to present at several ... Healthcare Conference in BostonDate: , Thursday, September ... of America Merrill Lynch Global Healthcare Conference ...
(Date:9/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/twqfk6/global_medical ) has ... Packaging Market - By Packaging type, Regions and Vendors ... report to their offering. The growth ... its end use industry, i.e., Medical devices industry. More ... devices so as to be tamper evident, and child-resistant. ...
(Date:9/3/2015)... 2015 , Novel ideas ... High need for translation of findings into ... of life   , On occasion of ... ® , young scientists from across Europe ... novel ideas with potential for achieving major advances in pain management. ...
Breaking Medicine Technology:Ascendis Pharma A/S to Present at Three Upcoming Investor Conferences 2Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 2Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 3Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 4Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 5Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 6Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 7Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 8Results of Pain Research Projects Raise Aspiration for Advanced Pain Treatment 2Results of Pain Research Projects Raise Aspiration for Advanced Pain Treatment 3Results of Pain Research Projects Raise Aspiration for Advanced Pain Treatment 4Results of Pain Research Projects Raise Aspiration for Advanced Pain Treatment 5
... SAN FRANCISCO, Calif., Jan. 9 Rigel,Pharmaceuticals, Inc. ... has begun,enrolling patients in a Phase 1 study ... orally available, potent inhibitor of Janus Kinase,3 (JAK3), ... arthritis,(RA), psoriasis and other immune disorders. In preclinical ...
... INDIANAPOLIS, Jan. 9 Semafore Pharmaceuticals Inc.,today ... Research (2008; Vol. 68,Issue 1: 206-215) reports ... antitumor and antiangiogenic activity., The paper, ... Prodrug, SF1126, with Antitumor and Antiangiogenic Activity," ...
Cached Medicine Technology:Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders 2Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders 3Semafore's SF1126 Exhibits Antitumor and Antiangiogenic Activity 2
(Date:9/4/2015)... Dallas, Texas (PRWEB) , ... September 04, 2015 ... ... the recipient of three separate “Partner of the Year” awards at this year’s ... included being named Microsoft’s 2015 “Partner of the Year” Award Winner for Data ...
(Date:9/4/2015)... ... ... consumers are looking for a quick and convenient way to produce a hot remedy for ... provide a quick and simple way to brew a hot cup of cold remedy when ... result, they enhance comfort and health. The invention features a novel design that is lightweight, ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... and development of its first neighborhood created specifically for adults with intellectual, developmental ... the Phoenix Metro area and feature 30 cottage or “pocket” homes. In this ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... products, has a Labor Day offer that cannot be passed up. FiltersFast.com, ... up on necessary air and water filtration product replacements. Take advantage of this ...
(Date:9/3/2015)... ... September 03, 2015 , ... Allied Anesthesia is proud to announce ... the norm not the exception. , St. Jude was recently named one of the ... Association, making it one of only 10 hospitals in the state to earn the ...
Breaking Medicine News(10 mins):Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 3
... , , ... and a global leader in the development and delivery of customizable ... be showcasing recent enhancements to Ovid Universal Search, our first-to-market cross-platform ... on the American Psychological Association,s (APA,s) Thesaurus of Psychological Index ...
... PHOENIX, Dec. 1 Abrazo Media Relations-- The Center for ... Mesa, Arizona announces the addition of orthopaedic surgeon Dr. J. ... trained in sports medicine and orthopaedic surgery after recently completing ... he focused on adult and pediatric orthopaedic sports medicine. He ...
... 30 November 2009. Performing surgical operations without leaving ... become a reality. This is demonstrated by the recent ... Surgery), an innovative surgical approach that allows surgical access ... advantageous for the patient: lack of scars, shorter hospital ...
... to successfully obtain information about the cost of medical ... improve price transparency, according to a new study. ... from less than one-third of the hospitals they approached ... those allowed under California law, according to the findings ...
... to academic achievement, study finds , TUESDAY, Dec.1 (HealthDay ... may boost brainpower, making for better school grades and ... , Given that most doctors and laypeople know (or ... on healthy bodies, the authors of a new study, ...
... ADDISON, Texas, Dec. 1 For many employers, the issue ... an employee benefit, it,s providing for the needs of their ... effort, with the help of Concentra, by opening a worksite ... and convenient health care services directly to employees and their ...
Cached Medicine News:Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 2Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 3Health News:Orthopaedic Surgeon Dr. J. Hunt Udall Joins the Center for Pediatric Orthopaedics and Scoliosis as One of Few Trained Doctors to Perform Minimally Invasive Hip Arthroscopy 2Health News:Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus 2Health News:Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus 3Health News:Hospital price transparancy laws in California fall short, study finds 2Health News:Exercise May Lead to a Smarter, More Successful You 2Health News:Exercise May Lead to a Smarter, More Successful You 3Health News:Hobby Lobby Selects Concentra to Open Health Center 2Health News:Hobby Lobby Selects Concentra to Open Health Center 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: